Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III perioperative GC versus HD-MVAC in locally advanced bladder urothelial carcinoma
2012-000563-25Phase 3Completed
- Sponsor
- Rouen University Hospital
- Start
- Sep 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, cisplatin, methotrexate, vinblastine, doxorubicin and 1 more in transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Rouen University Hospital. Primary endpoint: Progression-free survival at 3 years. Started Sep 2012; status: completed.
02
Drugs
gemcitabinecisplatinmethotrexatevinblastinedoxorubicin
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2012-000563-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000563-25.